Hyperkalemic periodic paralysis: Difference between revisions

Jump to navigation Jump to search
Line 27: Line 27:
This condition is inherited in an [[autosomal dominant]] pattern, which means one copy of the altered gene in each cell is sufficient to cause the disorder.
This condition is inherited in an [[autosomal dominant]] pattern, which means one copy of the altered gene in each cell is sufficient to cause the disorder.


==Disease in horses==
===Symptoms and presentation===
This inherited disease is characterized by uncontrollable [[muscle twitching]] and substantial [[muscle weakness]] or [[paralysis]] among affected horses. HYPP is a dominant disorder; therefore [[Zygosity|heterozygotes]] bred to [[genotype|genotypically]] normal horses will still likely produce clinically affected offspring 50% of the time.


===Inheritance and prevalence===
Horses affected with HYPP can be treated with some possibility of reducing symptoms, but the degree that medical treatment helps varies from horse to horse.  Therefore, horses with HYPP should only be ridden by experienced riders, if anyone, because episodes of paralysis can come on very suddenly and a rider has to be extremely alert to recognize an impending episode which may cause the horse to lose control of its body. 
The disease is most common in the bloodline of the famous Appendix [[American Quarter Horse]] stallion [[Impressive (horse)|Impressive]], who has over 55,000 living descendants [[as of 2003]]. Although the disease is primarily limited to the American Quarter Horse breed and closely related breeds such as [[American Paint Horse]]s and [[Appaloosa]]s at this time, cross-breeding has begun to extend it to grade horses and ponies. The spread of the disease is perpetuated by the favorable judgings given to diseased horses in showing, due to the extremely large, bulky muscles the N/H and H/H horses carry, (as opposed to the N/N horses), that judges favor.
===Genetics===
In 1994, researchers at the [[University of Pittsburgh]], with a grant from various horse organizations, isolated the genetic mutation responsible for the problem and developed a [[blood test]] for it. Using this test, horses may be identified as:
* H/H, meaning they have the mutation and it is [[Zygosity|homozygous]]. These horses always pass on the disease.
* N/H, meaning they have the mutation and it is [[Zygosity|heterozygous]]. These horses are affected to a lesser degree, and pass on the disease 50% of the time.
* N/N, meaning they do not have the mutation and cannot pass it on, even if they are  descendants of Impressive.
===Regulation===
Recently, horse organizations have begun instituting rules to attempt to eliminate this widespread disease. The [[American Quarter Horse Association]] (AQHA) now mandates testing for the "Impressive" mutation and will no longer register [[Zygosity|homozygous]] (H/H) foals as of [[2007]], with discussion of [[Zygosity|heterozygous]] (N/H) foals pending. The [[Appaloosa Association]] will no longer accept homozygous foals as of [[2008]]. It is believed that both primary palomino registries will exclude any foal carrying the "Impressive" mutation as of [[2007]]. The main organization affected by HYPP that has not yet taken action is the [[American Paint Horse Association]] (APHA), although many other smaller organizations are also affected.


==References==
==References==

Revision as of 19:45, 6 January 2009

Hyperkalemic periodic paralysis
ICD-10 G72.3
ICD-9 359.3
OMIM 170500
DiseasesDB 6252
MeSH D020513

WikiDoc Resources for Hyperkalemic periodic paralysis

Articles

Most recent articles on Hyperkalemic periodic paralysis

Most cited articles on Hyperkalemic periodic paralysis

Review articles on Hyperkalemic periodic paralysis

Articles on Hyperkalemic periodic paralysis in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Hyperkalemic periodic paralysis

Images of Hyperkalemic periodic paralysis

Photos of Hyperkalemic periodic paralysis

Podcasts & MP3s on Hyperkalemic periodic paralysis

Videos on Hyperkalemic periodic paralysis

Evidence Based Medicine

Cochrane Collaboration on Hyperkalemic periodic paralysis

Bandolier on Hyperkalemic periodic paralysis

TRIP on Hyperkalemic periodic paralysis

Clinical Trials

Ongoing Trials on Hyperkalemic periodic paralysis at Clinical Trials.gov

Trial results on Hyperkalemic periodic paralysis

Clinical Trials on Hyperkalemic periodic paralysis at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Hyperkalemic periodic paralysis

NICE Guidance on Hyperkalemic periodic paralysis

NHS PRODIGY Guidance

FDA on Hyperkalemic periodic paralysis

CDC on Hyperkalemic periodic paralysis

Books

Books on Hyperkalemic periodic paralysis

News

Hyperkalemic periodic paralysis in the news

Be alerted to news on Hyperkalemic periodic paralysis

News trends on Hyperkalemic periodic paralysis

Commentary

Blogs on Hyperkalemic periodic paralysis

Definitions

Definitions of Hyperkalemic periodic paralysis

Patient Resources / Community

Patient resources on Hyperkalemic periodic paralysis

Discussion groups on Hyperkalemic periodic paralysis

Patient Handouts on Hyperkalemic periodic paralysis

Directions to Hospitals Treating Hyperkalemic periodic paralysis

Risk calculators and risk factors for Hyperkalemic periodic paralysis

Healthcare Provider Resources

Symptoms of Hyperkalemic periodic paralysis

Causes & Risk Factors for Hyperkalemic periodic paralysis

Diagnostic studies for Hyperkalemic periodic paralysis

Treatment of Hyperkalemic periodic paralysis

Continuing Medical Education (CME)

CME Programs on Hyperkalemic periodic paralysis

International

Hyperkalemic periodic paralysis en Espanol

Hyperkalemic periodic paralysis en Francais

Business

Hyperkalemic periodic paralysis in the Marketplace

Patents on Hyperkalemic periodic paralysis

Experimental / Informatics

List of terms related to Hyperkalemic periodic paralysis

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Hyperkalemic periodic paralysis (HYPP), also known as Impressive Syndrome, is an inherited autosomal dominant disorder which affects sodium channels in muscle cells and the ability to regulate potassium levels in the blood. It is most commonly associated with horses, but also occurs in humans, where it is also called Gamstorp episodic adynamy.

Disease in humans

Although much rarer, hyperkalemic periodic paralysis has also been observed in humans. In humans the disorder causes episodes of extreme muscle weakness, usually beginning in the second decade and depending on the type and severity of the HYPP will increase or stabilize until the fourth or fifth decade where attacks usually decline and can altogether stop. Factors that can trigger attacks include rest after exercise, potassium-rich foods, stress, fatigue, certain pollutants (eg: Cigarette smoke) and periods of fasting. Muscle strength improves between attacks, although many affected people may have increasing bouts of muscle weakness as time goes on (abortive attacks). Sometimes with HYPP those affected may experience degrees of muscle stiffness and spasms (myotonia) in the affected muscles. This can be caused by the same things that trigger the paralysis, dependant on the type of mytonia. (See also paramyotonia).

Some people with hyperkalemic periodic paralysis have increased levels of potassium in their blood (hyperkalemia) during attacks. In other cases, attacks are associated with normal blood potassium levels (normokalemia). Ingesting potassium can trigger attacks in affected individuals, even if blood potassium levels do not go up.

The most common underlying cause is one of several possible point mutations in the gene SCN4A. The SCN4A gene provides instructions for making a protein that plays an essential role in muscles used for movement (skeletal muscles). For the body to move normally, these muscles must tense (contract) and relax in a coordinated way. Muscle contractions are triggered by the flow of certain positively charged atoms (ions), including sodium, into muscle cells. The SCN4A protein forms channels that control the flow of sodium ions into these cells. Mutations in the SCN4A gene alter the usual structure and function of sodium channels. The altered channels cannot properly regulate the flow of sodium ions into muscle cells, which reduces the ability of skeletal muscles to contract. Because muscle contraction is needed for movement, a disruption in normal ion transport leads to episodes of muscle weakness or paralysis.

This condition is inherited in an autosomal dominant pattern, which means one copy of the altered gene in each cell is sufficient to cause the disorder.


References

External links

Template:PNS diseases of the nervous system Template:SIB

Template:WH Template:WikiDoc Sources Template:Jb1